Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Web link to Cantor fireside chat not included.

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Sep 09, 2024 11:03am

90 Views

Post# 36214727

RE:Web link to Cantor fireside chat not included.

They are telling this on the day of the first event and we're not invited to listen. It sounds like hey we're going fishing just in case we catch something before whatever the next Q or p1 data brings on. It's difficult to follow the strategy behind this.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023